FDA Commish Hamburg Gets Fond Farewell
This article was originally published in The Gray Sheet
Executive Summary
FDA Commissioner Margaret Hamburg said she will step down from the agency after six years in the post. She is being widely praised by lawmakers and industry as an effective bureaucrat who has worked to improve FDA’s regulatory processes and speed the path to market for new products.
You may also be interested in...
FDA Nominee Califf Seeks Clinical Trial, Combo Product Reforms
President Obama nominated Robert Califf for FDA commissioner, and Senate HELP Chairman Lamar Alexander said the committee "will move promptly" to consider the nomination. If confirmed, he would be expected to lead reforms of the combination products review process, among other initiatives. However, while the initial positive response from Sen. Alexander suggests the possibility of a smooth confirmation, it certainly isn't guaranteed.
Hamburg: Neither U.S. Nor EU Device Regulation Has It Completely Right
During her final public appearance at the National Press Club, outgoing FDA Commissioner Margaret Hamburg defended her tenure and said she was leaving a stronger FDA than the one she inherited. Asked about the agency's device regulatory process, she said she didn't know if FDA or Europe had struck the right balance but said more work needs to be done.
Commissioner Defends FDA On Duodenoscope, LDT Actions At Senate Hearing
In her last appearance before a Senate committee March 10, FDA Commissioner Margaret Hamburg presented a strong defense of FDA’s actions to address contaminated duodenoscopes, regulation of lab developed tests and other hot button issues raised by Senators, who also praised her leadership at FDA.